Clinical trial
CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma
NCT00033267 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00033267 |
|---|---|
| Title | CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of CCI-779 in Previously Treated Patients With Mantle Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Mantle Cell Lymphoma |
| Intervention type | Drug |
| Interventions | temsirolimus |
| Enrollment | 27 |
| Start date | Apr 1, 2002 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 3, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: